Technical Analysis for APTO - Aptose Biosciences, Inc.

Grade Last Price % Change Price Change
F 0.28 0.73% 0.00
APTO closed down 23.97 percent on Wednesday, November 20, 2024, on 10.19 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.73%
Expansion Breakdown Bearish Swing Setup 0.73%
Volume Surge Other 0.73%
Wide Range Bar Range Expansion 0.73%
Lower Bollinger Band Walk Weakness 0.73%
New 52 Week Low Weakness 0.73%
Below Lower BB Weakness 0.73%
Gapped Down Weakness 0.73%
Lower Bollinger Band Touch Weakness 0.73%
Oversold Stochastic Weakness 0.73%

   Recent Intraday Alerts

Alert Time
2x Volume Pace about 4 hours ago
1.5x Volume Pace about 4 hours ago
3x Volume Pace about 4 hours ago
Gap Up Partially Closed about 4 hours ago
Gapped Up (Partial) about 4 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aptose Biosciences, Inc. Description

Aptose Biosciences Inc., a biopharmaceutical company, is engaged in the discovery, research, and development of novel anticancer therapies in Canada. The company's pipeline of cancer drug candidates includes small molecule therapies and immunotherapy. Its lead program, LOR-253, an anticancer agent, which has completed Phase I clinical trail for the treatment of solid tumors, as well as undergoing Phase II clinical trials for the treatment of relapsed/refractory hematologic malignancies. The company's discovery stage products include LOR-500, a MELK Inhibitor for Oncology, as well as small molecule programs. The company is also developing RNA-targeted therapies, including LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; and Virulizin, a novel immunotherapy agent that has completed three Phase I/II clinical studies in solid tumors and pancreatic cancers, as well as completed a randomized placebo-controlled Phase III clinical trial for the treatment of pancreatic cancer in combination with gemcitabine. In addition, its preclinical stage products comprise LOR-220, a novel small molecule for drug-resistant bacterial infections; and IL-17E1, an immuno-modulator for oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Drugs Immunotherapy Oncology Acute Myeloid Leukemia Pancreatic Cancer Cancer Therapies Hematologic Malignancies Targeted Therapy Bacterial Infections Small Molecule Therapies Treatment Of Acute Myeloid Leukemia Preclinical Stage Product Phosphoinositide 3 Kinase Inhibitor Stage Products Bemcentinib Gemcitabine Preclinical Stage Products Treatment Of Pancreatic Cancer Drug Resistant Bacterial Infections

Is APTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.9077
52 Week Low 0.2701
Average Volume 118,551
200-Day Moving Average 0.90
50-Day Moving Average 0.38
20-Day Moving Average 0.38
10-Day Moving Average 0.37
Average True Range 0.03
RSI (14) 27.01
ADX 20.03
+DI 9.48
-DI 27.19
Chandelier Exit (Long, 3 ATRs) 0.32
Chandelier Exit (Short, 3 ATRs) 0.37
Upper Bollinger Bands 0.43
Lower Bollinger Band 0.32
Percent B (%b) -0.46
BandWidth 28.47
MACD Line -0.01
MACD Signal Line -0.01
MACD Histogram -0.0085
Fundamentals Value
Market Cap 4.29 Million
Num Shares 15.7 Million
EPS -7.72
Price-to-Earnings (P/E) Ratio -0.04
Price-to-Sales 0.00
Price-to-Book 4.10
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.37
Resistance 3 (R3) 0.38 0.36 0.35
Resistance 2 (R2) 0.36 0.33 0.35 0.35
Resistance 1 (R1) 0.31 0.32 0.30 0.31 0.34
Pivot Point 0.29 0.29 0.29 0.29 0.29
Support 1 (S1) 0.25 0.27 0.24 0.24 0.20
Support 2 (S2) 0.23 0.25 0.22 0.20
Support 3 (S3) 0.19 0.23 0.19
Support 4 (S4) 0.18